Cargando…
A randomized non-inferiority trial of therapeutic strategy with immunosuppressants versus biologics for Vogt-Koyanagi-Harada disease
Biologics are increasingly used to treat Vogt-Koyanagi-Harada disease, but head-to-head comparisons with conventional immunosuppressants are lacking. Here in this randomized trial (Chinese Clinical Trial Registry, ChiCTR2100043061), we assigned 110 patients (27 early-phase and 83 late-phase) to cycl...
Autores principales: | Zhong, Zhenyu, Dai, Lingyu, Wu, Qiuying, Gao, Yu, Pu, Yanlin, Su, Guannan, Lu, Xiaorong, Zhang, Fuxiang, Tang, Chong, Wang, Yao, Zhou, Chunjiang, Yang, Peizeng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10290648/ https://www.ncbi.nlm.nih.gov/pubmed/37355662 http://dx.doi.org/10.1038/s41467-023-39483-5 |
Ejemplares similares
-
Association of ZC3HAV1 single nucleotide polymorphisms with the susceptibility of Vogt-Koyanagi-Harada Disease
por: Wu, Qiuying, et al.
Publicado: (2023) -
Integrated Analysis of Key Pathways and Drug Targets Associated With Vogt-Koyanagi-Harada Disease
por: Chen, Zhijun, et al.
Publicado: (2020) -
Identification of Urine Metabolic Biomarkers for Vogt-Koyanagi-Harada Disease
por: Chang, Rui, et al.
Publicado: (2021) -
Analyses of circRNA and mRNA Profiles in Vogt–Koyanagi–Harada Disease
por: Shu, Jia, et al.
Publicado: (2021) -
Optical Coherence Tomographic Features and Prognostic Values of Macular Edema in Vogt-Koyanagi-Harada Disease
por: Qin, Peng, et al.
Publicado: (2022)